Seer, Inc. Stock Price, News & Analysis

Seer (NASDAQ: SEER) has unveiled its new Proteograph® Product Suite, featuring the Proteograph ONE Assay and SP200 Automation Instrument at ASMS 2025. The enhanced platform achieves groundbreaking improvements in proteomic analysis capabilities, processing over 1,000 samples per week per instrument - double the previous throughput. The new workflow reduces per-sample analysis costs by 60% compared to its 2021 release while identifying up to 10 times more proteins than traditional mass spec workflows.

Key advancements include automated run times under 5 hours for 80-sample batches, reduced operator-induced variability, and enhanced reproducibility. The system enables large-scale biomarker discovery, longitudinal disease studies, and comprehensive multi-center research. The new Proteograph Product Suite will be commercially available from June 1, 2025, through direct purchases and Seer's Technology Access Center.

Seer (NASDAQ: SEER) reported its Q1 2025 financial results, achieving revenue of $4.2 million, a 37% increase from $3.1 million in Q1 2024. The growth was primarily driven by higher product and service revenue. Product revenue reached $2.9 million, while service revenue was $1.2 million. The company reported a gross margin of 49% and a net loss of $19.9 million, improved from $20.7 million in the prior year.

Operating expenses decreased 14% to $22.8 million, including $4.5 million in stock-based compensation. Seer ended Q1 with approximately $285 million in cash and investments. The company secured a significant contract for a 10,000-sample study and maintained its full-year 2025 revenue guidance of $17-18 million, representing 24% growth at the midpoint over 2024.

Seer Inc (Nasdaq: SEER), a life sciences company focused on proteomics platform commercialization, has scheduled its first quarter 2025 financial results announcement for May 13, 2025. The company will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day. Investors can access the live webcast through the Investor section at investor.seer.bio, where a replay will also be available after the event.

Seer (Nasdaq: SEER) reported Q4 and full year 2024 financial results. Q4 revenue was $4.0M, down 10% YoY, while full-year revenue reached $14.2M, a 15% decrease from 2023. The company shipped 10 instruments in 2024, bringing total installations to 72.

Q4 gross profit was $2.0M with 51% margin, while operating expenses increased 5% to $25.5M. Net loss widened to $21.7M in Q4 2024 from $17.8M in Q4 2023. For the full year, net loss was $86.6M compared to $86.3M in 2023.

Notable developments include a new cell lysis proteomics application for the Proteograph XT workflow and a share repurchase of 6.5M shares at $1.82/share, reducing outstanding shares by 10%. The company ended 2024 with $300M in cash and investments. For 2025, Seer projects revenue of $17-18M, representing 24% growth at midpoint.

Seer (Nasdaq: SEER), a pioneering life sciences company focused on proteomics platform commercialization, has announced its participation in the TD Cowen 45th Annual Healthcare Conference in Boston, MA.

The company's management team will engage in a fireside chat scheduled for Tuesday, March 4th at 11:50 a.m. Eastern Time (8:50 a.m. Pacific Time). Investors and interested parties can access a live webcast of the session through the Investor section of Seer's website at investor.seer.bio. An archived replay will be made available on the company's website after the conference concludes.

Seer Inc (Nasdaq: SEER) announced its participation in the 21st Annual US HUPO Conference in Philadelphia from February 22-26, 2025. The company will showcase new findings and host a seminar featuring groundbreaking research in cancer therapy using their Proteograph™ Product Suite.

The seminar will highlight Dr. Jinjun Shi's research from Brigham and Women's Hospital and Harvard Medical School, focusing on a novel co-delivery therapeutic platform that simultaneously targets cancer vulnerabilities using siRNA while activating tumor suppressors with mRNA. The study specifically addresses prostate cancer, the second leading cause of cancer death among men in the US.

Seer recently introduced a new workflow for deep cellular proteome analysis, adding to their existing 10+ Proteograph protocols for various sample types. The conference will also feature presentations from Seer and collaborators on tissue biology, cardiometabolic dysfunction biomarkers, and mass spectrometry proteomics throughput advancements.

Seer (Nasdaq: SEER) has announced it will release its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. The life sciences company, which specializes in proteomics platform technology, will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day. Investors can access the live webcast through the Investor section of Seer's website at investor.seer.bio, where an archived replay will also be available after the event.

Seer (Nasdaq: SEER), a pioneer in proteomics platform technology, has announced its participation in the J.P. Morgan 43rd Annual Healthcare Conference in San Francisco. The company's management team will deliver a presentation and engage in a Q&A session on Wednesday, January 15th at 3:00 p.m. Pacific Time / 6:00 p.m. Eastern Time.

Investors and interested parties can access a live webcast of the session through the Investor section of Seer's website at investor.seer.bio. For those unable to attend the live presentation, an archived replay will be made available on the company's website after the conference concludes.

Seer (Nasdaq: SEER) has been ranked No. 57 on the 2024 Deloitte Technology Fast 500™, achieving a remarkable 2,440% revenue growth. The company attributes this growth to increased adoption of its Proteograph Product Suite and customer discoveries across neurodegenerative disease, cancer, and metabolic disease. Key achievements include launching a technology access center in Europe, platform usage on the SpaceX Inspiration4 mission, and establishing a co-marketing agreement with Thermo Fisher Scientific. This marks Seer's second consecutive appearance on the list, improving from their No. 5 ranking in 2023.